8-K: Centene Reports Q3 Loss on $6.7B Impairment, Raises 2025 EPS Outlook

Centene Corporation reported a GAAP diluted loss per share of $(13.50) for the third quarter of 2025 due to a $6.7 billion goodwill impairment, while simultaneously raising its full-year adjusted diluted EPS forecast to at least $2.00.

Summary

• Reported a GAAP diluted loss per share of $(13.50) for Q3 2025, primarily driven by a non-cash goodwill impairment.
• Achieved adjusted diluted earnings per share of $0.50 for Q3 2025, including a $0.10 benefit from a low adjusted effective tax rate.
• Recorded a significant non-cash goodwill impairment of $6.7 billion in Q3 2025, attributed to market conditions in July 2025, including the One Big Beautiful Bill Act and a decline in the company's stock price.
• Total revenues increased 22% to $49.69 billion in Q3 2025 from $42.023 billion in Q3 2024, with premium and service revenues rising to $44.898 billion from $36.899 billion.
• The Health Benefits Ratio (HBR) increased to 92.7% in Q3 2025 from 89.2% in Q3 2024, driven by increased Marketplace medical costs, lower Marketplace estimated risk adjustment revenue, and program changes in the PDP business due to the Inflation Reduction Act (IRA).
• The SG&A expense ratio improved to 7.0% in Q3 2025 from 8.3% in Q3 2024, primarily due to leveraging expenses over higher revenues and growth in the lower SG&A PDP business.
• Cash flow provided by operations was $1.4 billion for Q3 2025, mainly due to the timing of claims and other payments.
• Increased the full year 2025 adjusted diluted EPS forecast by $0.25 to at least $2.00, up from the $1.75 forecast discussed in July.

Sentiment

Score: 4

Explanation: The significant non-cash goodwill impairment leading to a large GAAP loss is a major negative, reflecting past overvaluations or adverse market/regulatory changes. However, the increase in the full-year adjusted EPS forecast and strong revenue growth, coupled with improved SG&A efficiency, indicate underlying operational resilience and a positive forward trajectory for core business performance, mitigating some of the negative sentiment from the impairment.

Positives

• Increased the full year 2025 adjusted diluted EPS forecast by $0.25 to at least $2.00, demonstrating an improved outlook for core profitability.
• Adjusted diluted EPS of $0.50 in Q3 2025, benefiting from a low adjusted effective tax rate.
• Total revenues grew 22% to $49.69 billion in Q3 2025, with premium and service revenues up 22% to $44.898 billion.
• Strong revenue growth in Commercial (up 26%) and Medicare (up 66%) segments.
• SG&A expense ratio improved to 7.0% in Q3 2025 from 8.3% in Q3 2024, indicating better cost management and leveraging.
• Cash flow provided by operations was robust at $1.4 billion for Q3 2025.
• Total at-risk membership increased to 27,968,100 from 25,893,000 year-over-year.
• Commercial and Medicare segment results were in line with expectations.
• Named in the inaugural 2025 Forbes America's Best Employers for Company Culture list.
• Engaged in community investments through the Centene Foundation and subsidiaries, supporting mental health and community health centers.

Negatives

• Reported a GAAP diluted loss per share of $(13.50) for Q3 2025, primarily due to a $6.7 billion non-cash goodwill impairment.
• The $6.7 billion goodwill impairment resulted in a corresponding reduction of retained earnings and increased the debt-to-capital ratio to 45.5% at September 30, 2025.
• Health benefits ratio (HBR) increased to 92.7% in Q3 2025 from 89.2% in Q3 2024, indicating higher medical costs.
• Increased Marketplace medical costs, lower Marketplace estimated risk adjustment revenue, and program changes due to the Inflation Reduction Act (IRA) negatively impacted HBR.
• Higher medical costs in Medicaid, particularly in behavioral health and home health, contributed to the increased HBR.
• Medicaid membership decreased to 12,706,400 from 13,068,800 year-over-year.
• Medicare membership decreased to 1,013,200 from 1,129,900 year-over-year.
• The effective tax rate for Q3 2025 was significantly impacted by the non-deductible nature of the goodwill impairment.

Risks

• Ability to design and price competitive and actuarially sound products.
• Difficulty in accurately predicting and effectively managing health benefits and other operating expenses and reserves, including fluctuations in medical costs.
• Potential for rate cuts, insufficient rate changes, or other payment reductions or delays by government payors affecting government businesses.
• Impact of social, economic, and political conditions, geopolitical events, and state and federal policies, including funding for government-sponsored healthcare programs and changes in U.S. presidential administrations or Congress.
• Changes in federal or state laws or regulations, including income tax reform, the ACA, and regulations thereunder, which could reduce membership or profitability.
• Unanticipated increased healthcare costs due to changes in consumer and provider behaviors, inflation, and tariffs.
• Challenges in maintaining or improving CMS Star ratings and other quality scores, which could impact revenue and future growth.
• Intense competition for providers, broker distribution networks, contract reprocurements, and organic growth.
• Risks associated with managing information systems effectively and potential disruptions from business transactions, including acquisitions, divestitures, and changes in vendor relationships.
• Potential for future impairments to real estate, investments, and intangible assets.
• Risks related to changes in senior management, loss of key personnel, or inability to attract, hire, integrate, and retain skilled personnel.
• Membership and revenue declines or unexpected trends.
• Changes in healthcare practices, new technologies, and advances in medicine.
• Challenges in effectively and ethically using artificial intelligence and machine learning in compliance with applicable laws.
• Impact of macroeconomic conditions, including inflation, interest rates, and volatility in financial markets.
• Negative public perception of the Company and the managed care industry.
• Uncertainty concerning government shutdowns, debt ceilings, or funding.
• Tax matters.
• Disasters, climate-related incidents, acts of war or aggression, or major epidemics.
• Delays in the timing of regulatory approval of contracts, including due to protests.
• Expiration, suspension, or termination of contracts with federal or state governments.
• Difficulty predicting the timing or outcome of legal or regulatory audits, investigations, proceedings, or challenges to contract awards.
• Cyber-attacks or other data security incidents or failure to comply with applicable privacy, data, or security laws and regulations.
• Restrictions and limitations in connection with indebtedness and potential downgrade of corporate family or credit ratings.
• Availability of debt and equity financing on favorable terms.

Future Outlook

Centene Corporation has increased its full year 2025 adjusted diluted EPS forecast by $0.25 to at least $2.00, up from the $1.75 forecast discussed in July. The company also updated its full year 2025 GAAP diluted loss per share forecast to not exceed $(12.85). Management remains focused on driving margin improvement, delivering outcomes for members, and positioning the business for long-term success.

Management Comments

• "Our third quarter results and increased full year outlook demonstrate tangible progress against the near-term milestones we laid out for investors in July."
• "While much work remains ahead, our organization remains focused on driving margin improvement, delivering outcomes for our members, and positioning the business for long-term success."

Industry Context

The filing highlights challenges from increased Marketplace medical costs and program changes due to the Inflation Reduction Act (IRA) in the Medicare Prescription Drug Plan (PDP) business, reflecting broader industry pressures on healthcare providers and insurers. The goodwill impairment, partly attributed to the "One Big Beautiful Bill Act," suggests a significant regulatory or legislative impact on the company's valuation, which could be a sector-wide concern for managed care organizations. Despite these headwinds, Centene's growth in Commercial and Medicare segments, alongside improved SG&A efficiency, indicates resilience and strategic adaptation within a dynamic healthcare landscape. The decline in Medicaid membership could reflect ongoing redeterminations or shifts in state programs, a trend impacting many Medicaid-focused insurers.

Comparison to Industry Standards

• The $6.7 billion non-cash goodwill impairment, partly attributed to the "One Big Beautiful Bill Act," suggests a significant impact from specific legislation or market conditions that could affect other large managed care organizations with similar business lines or goodwill valuations.
• The increase in Health Benefits Ratio (HBR) to 92.7% (from 89.2%) driven by Marketplace medical costs and IRA program changes in PDP indicates that Centene is experiencing similar cost pressures seen across the health insurance industry, particularly in government-sponsored programs and exchange plans. For example, competitors like UnitedHealth Group or Elevance Health might also report increased medical cost trends in their commercial and government segments.
• The improvement in SG&A expense ratio to 7.0% (from 8.3%) demonstrates effective cost leveraging, which is a key operational efficiency metric for large-scale insurers. This could position Centene favorably compared to peers struggling with administrative cost control amidst revenue growth.
• The increase in adjusted diluted EPS forecast by $0.25 to at least $2.00, despite the large GAAP loss, suggests that Centene's underlying operational performance (excluding non-cash impairments) is improving, potentially outperforming some competitors facing similar market and regulatory challenges without such a positive revision to their outlook.

Stakeholder Impact

• Shareholders: Will experience a significant GAAP loss per share due to the goodwill impairment, potentially impacting stock price. However, the raised adjusted EPS forecast might signal underlying operational strength and future profitability, which could be a positive for long-term investors.
• Employees: Recognized as a "Best Employer for Company Culture," suggesting a positive internal environment. Community engagement initiatives also benefit local communities where employees reside.
• Customers (Members): The company's focus on "delivering outcomes for our members" and community health initiatives (e.g., Uvalde health center, mental health programs) indicate a commitment to member well-being and access to care.
• Suppliers/Providers: Higher medical costs in Medicaid and Marketplace suggest increased payments to providers, which could be beneficial for them, though the company aims for margin improvement.
• Creditors: The debt-to-capital ratio increased to 45.5% due to the goodwill impairment's impact on retained earnings, which could be a point of attention for creditors, although total debt remained stable and the revolving credit facility was undrawn.

Next Steps

• Host a conference call on October 29, 2025, at 9:00 a.m. ET to review financial results.
• Continue focusing on driving margin improvement.
• Continue delivering outcomes for members.
• Continue positioning the business for long-term success.

Key Dates

Recommendation

While the $6.7 billion goodwill impairment is a significant non-cash charge resulting in a substantial GAAP loss, it primarily reflects a revaluation of past acquisitions rather than current operational distress. The company's decision to raise its full-year adjusted EPS forecast, coupled with strong revenue growth and improved SG&A efficiency, indicates a healthy underlying business performance. The increase in HBR is a concern, but management's focus on margin improvement suggests efforts to address this. Given the mixed signals – a large one-time impairment versus an improved operational outlook – a "hold" recommendation is appropriate. Investors should monitor future quarters for sustained operational improvements and how the company manages its HBR, especially in light of ongoing regulatory and market pressures. The stock may experience volatility due to the GAAP loss, but the adjusted outlook provides a floor for valuation.

Keywords

Centene, CNC, Healthcare, Managed Care, Q3 2025 Earnings, Financial Results, Goodwill Impairment, Adjusted EPS, Medicaid, Medicare, Marketplace, Health Benefits Ratio, SG&A Ratio, Revenue Growth, Membership, Financial Outlook, SEC Filing, 8-K